Molecular Analysis for Therapy Choice (MATCH)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Malignant Uterine Neoplasm | Recurrent Glioma | Melanoma | Recurrent Lymphoma | Recurrent Gastric Carcinoma | Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Recurrent Colon Carcinoma | Recurrent Liver Carcinoma | Bladder Carcinoma | Cervical Carcinoma | Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma | Breast Carcinoma | Recurrent Pancreatic Carcinoma | Recurrent Skin Carcinoma | Thyroid Gland Carcinoma | Advanced Malignant Solid Neoplasm | Prostate Carcinoma | Endometrial Carcinoma | Recurrent Esophageal Carcinoma | Refractory Lymphoma | Ovarian Carcinoma | Lymphoma | Recurrent Malignant Solid Neoplasm Recurrent Melanoma | Skin Carcinoma | Uterine Corpus Cancer | Recurrent Head and Neck Carcinoma | Recurrent Prostate Carcinoma | Esophageal Carcinoma | Refractory Plasma Cell Myeloma | Recurrent Cervical Carcinoma | Plasma Cell Myeloma | Head and Neck Carcinoma | Colorectal Carcinoma | Recurrent Bladder Carcinoma | Recurrent Lung Carcinoma | Recurrent Plasma Cell Myeloma | Recurrent Ovarian Carcinoma | Lung Carcinoma | Glioma | Recurrent Rectal Carcinoma | Pancreatic Carcinoma | Gastric Carcinoma | Colon Carcinoma | Rectal Carcinoma | Recurrent Colorectal Carcinoma | Refractory Malignant Solid Neoplasm
Age: Between 18 - 100 Years
Gender: Male or Female
Women of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration
Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival
Patients must have measurable disease
Patients must have tumor amenable to image guided or direct vision biopsy and be willing and able to undergo a tumor biopsy for molecular profiling; biopsy must not be considered to be more than minimal risk to the patient
Patient must not require the use of full dose coumarin-derivative anticoagulants such as warfarin; low molecular weight heparin is permitted for prophylactic or therapeutic use; stopping the anticoagulation for biopsy should be per site standard operating procedure (SOP)
Patients must have Eastern Cooperative Oncology Group (ECOG) performance status == 4 weeks prior to registration to Step 0
Patients must have discontinued steroids >= 1 week prior to registration to Step 0; patients with glioblastoma (GBM) must have been on stable dose of steroids, or be off steroids, for one week prior to registration to Step 0
Patients that are pregnant or breast feeding are excluded
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required